Acellular Pertussis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2017-12-26
Clinical Trial Update: Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants [Phase 3]
Phase 3 trial evaluating immunogenicity and safety of Infanrix-IPV/Hib (DTPa-IPV/Hib) in healthy Indian infants has been withdrawn.